Last edition
News about "Redemplo"
China's NMPA Approves Sanofi-Licensed Myqorzo and Redemplo for Rare Cardiac and Lipid Disorders
Myqorzo and Redemplo approvals by NMPA expand treatment options for obstructive hypertrophic cardiomyopathy and familial chylomicronaemia syndrome in adult patients across Greater China.
Redemplo | 17/01/2026 | By News Bureau | 307
China's NMPA Approves Sanofi-Licensed Myqorzo and Redemplo for Rare Cardiac and Lipid Disorders
Myqorzo and Redemplo approvals by NMPA expand treatment options for obstructive hypertrophic cardiomyopathy and familial chylomicronaemia syndrome in adult patients across Greater China.
Redemplo | 17/01/2026 | By News Bureau | 307
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy